Effect of fluconazole on the pharmacokinetics and pharmacodynamics of oral and rectal bromazepam: An application of electroencephalography as the pharmacodynamic method

Journal of Clinical Pharmacology

Volumn 42, Issue 2, 2002, Pages 183-191

  Ohtani, Yasukiyo ^a   Kotegawa, Tsutomu ^a   Tsutsumi, Kimiko ^a   Morimoto, Takuya ^a   Hirose, Yumiko ^a   Nakano, Shigeyuki ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BROMAZEPAM; FLUCONAZOLE; PLACEBO; SENIRAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; GASTROINTESTINAL TRACT; HUMAN; MALE; NORMAL HUMAN; PHARMACODYNAMICS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BROMAZEPAM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ELECTROENCEPHALOGRAPHY; FLUCONAZOLE; GABA MODULATORS; HALF-LIFE; HUMANS; MALE; PSYCHOMOTOR PERFORMANCE; SLEEP STAGES;

EID: 0036152237     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700222011229     Document Type: Article

References (40)

1. Pharmacokinetic-pharmacodynamic relationships for benzodiazepines
2. Pharmacokinetics and pharmacodynamics of oral diazepam: Effect of dose, plasma concentration, and time
3. Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs
4. Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo
5. Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: Kinetic-dynamic studies
6. Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences
7. Metabolites of bromazepam, a benzodiazepine, in the human, dog, rat, and mouse
8. Biopharmaceutical and clinical pharmacokinetic profile of bromazepam
9. Bromazepam pharmacokinetics: Influence of age, gender, oral contraceptives, cimetidine, and propranolol
10. Influence of multiple-dose administration of fluvoxamine on the pharmacokinetics of the benzodiazepines bromazepam and lorazepam : A randomized, crossover study
11. Differential inhibition of individual human liver cytochromes P-450 by cimetidine
12. Selective serotonin reuptake inhibitors and CNS drug interactions
13. Effect of azole antifungals on human microsomal metabolism of diclofenac and midazolam
14. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism
15. Effect of fluconazole dose on the extent of fluconazole-triazolam interaction
16. The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam
17. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam
18. Pharmacokinetics of rectal drug administration, part 1
19. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues
20. Biotransformation enzymes in human intestine: Critical low levels in the colon
21. Determination of bromazepam in plasma and its main metabolites in urine by reversedphase high-performance liquid chromatography
22. Absence of significant interaction of fluconazole with cyclosporin
23. Interaction of fluconazole with cyclosporin
24. Drug interactions with fluconazole
25. Interaction of fluconazole with cyclosporin
26. Interaction of fluconazole and cyclosporin
27. Interaction of fluconazole with cyclosporin A
28. Fluconazole-cyclosporin interaction: A dose dependent effect?
29. The use of fluconazole and itraconazole in the treatment of Candida albicans infections: A review
30. Antifungal agent
31. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174
32. Pharmacokinetics of bromazepam (suppository) in man
33. Pharmacokinetics of bromazepam (KL-001) following the rectal and oral administration in man
34. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole
35. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine
36. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism
37. Ring-opening decomposition of bromazepam in acidic media
38. Kinetics of the acid hydrolysis of diazepam, bromazepam, and flunitrazepam in aqueous and micellar systems
39. Acidic hydrolysis of bromazepam studied by high performance liquid chromatography: Isolation and identification of its degradation products
40. Degradation of bromazepam by the intestinal microflora